Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Public ClinicalTrials.gov record NCT03830866. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Study identification
- NCT ID
- NCT03830866
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 770 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Durvalumab Biological
- external beam radiation therapy (EBRT) + brachytherapy Radiation
Drug · Biological · Radiation
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Female
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2019
- Primary completion
- Jan 19, 2022
- Completion
- Jul 2, 2023
- Last update posted
- Jul 25, 2024
2019 – 2023
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85016 | — |
| Research Site | La Jolla | California | 92093 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | Fort Myers | Florida | 33905 | — |
| Research Site | Miami | Florida | 33136 | — |
| Research Site | Augusta | Georgia | 30912 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Lake Success | New York | 11042 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | Cleveland | Ohio | 44111 | — |
| Research Site | Cleveland | Ohio | 44124 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Dallas | Texas | 75390 | — |
| Research Site | Spring | Texas | 77380 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03830866, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 25, 2024 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03830866 live on ClinicalTrials.gov.